Sequence Specificity, Conformation, and Recognition by HMG1
Protein of Major DNA Interstrand Cross-links of Antitumor Dinuclear
Platinum Complexes*
Jana
Kasparkova
,
Nicholas
Farrell§, and
Viktor
Brabec
¶
From the
Institute of Biophysics, Academy of Sciences
of the Czech Republic, CZ-61265 Brno, Czech Republic and the
§ Department of Chemistry, Virginia Commonwealth University,
Richmond, Virginia 23284-2006
Received for publication, February 1, 2000
 |
ABSTRACT |
Interactions of high mobility group (HMG) domain
proteins with DNA modified by cisplatin plays a role in mechanisms
underlying its antitumor activity. A structural motif recognized by HMG
domain proteins on cisplatin-modified DNA is a stable, directional bend of the helix axis. In the present work, bending induced in DNA by major
adducts of a novel class of antitumor compounds, represented by the
formula
[{trans-PtCl(NH3)2}H2N(CH2)2-6NH2]Cl2,
was investigated. The oligodeoxyribonucleotide duplexes containing various site-specific interstrand cross-links of these bifunctional dinuclear platinum drugs were purified and characterized by
Maxam-Gilbert footprinting, chemical probing, and phasing assay. It was
demonstrated that the cross-links of the dinuclear compounds bent the
helix much less than those of cisplatin. Gel retardation assay revealed very weak recognition of DNA adducts of dinuclear complexes by HMG1
protein. Hence, the mediation of antitumor properties of dinuclear
platinum complexes by HMG domain proteins is unlikely so that
polynuclear platinum compounds may represent a novel class of platinum
anticancer drugs acting by a different mechanism than cisplatin and its
analogues. A further understanding of how polynuclear platinum
compounds modify DNA and how these modifications are processed in cells
should provide a rational basis for the design of new platinum drugs
rather than searching for cisplatin analogues.
 |
INTRODUCTION |
Platinum coordination complexes are effective chemotherapeutic
agents for the treatment of testicular cancer and are used in
combination regiments for a variety of other tumors, including ovarian,
cervical, bladder, lung, and those of the head and neck (1). The first
platinum compound introduced in the clinic is cis-diamminedichloroplatinum(II) (cisplatin).1
Later, two new platinum complexes,
cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) (carboplatin) and (trans-R,
R)1,2-diamminocyclohexaneoxalatoplatinum(II) (oxaliplatin), were
also introduced in the clinic, but they do not display a vastly
different spectrum of antitumor activity (2, 3). The intrinsic along
with acquired resistance and side effects observed in some patients
represent major limitations of the treatment of human tumors with the
platinum drugs currently used in the clinic. The need for improved
clinical protocols has prompted a search for new platinum
chemotherapeutic agents as well as a more complete understanding of the
cellular mechanisms underlying both antitumor efficacy and resistance.
Platinum anticancer drugs exert their cytotoxic effect by inducing DNA
damage with adducts formed being various types of cross-links (4-6).
Since the discovery of the antitumor efficiency of cisplatin in 1969, the only new platinum antitumor drugs introduced in the clinic are
direct structural analogues of cisplatin
(cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) differs from cisplatin only in the more inert leaving group
similar to (trans-R,
R)1,2-diamminocyclohexaneoxalatoplatinum(II), which still contains
as a carrier ligand 1,2-diaminocyclohexane). These new compounds
produce an array of adducts very similar to those of cisplatin (7, 8).
Therefore, it is not surprising that they induce similar biological
consequences (2, 3, 9).
In a search for novel classes of platinum antitumor compounds a
hypothesis that platinum drugs that bind to DNA in a fundamentally different manner to that of cisplatin will have altered pharmacological properties has been tested. This concept has already led to the synthesis of several new platinum antitumor compounds. One class of
these novel compounds comprises bifunctional dinuclear and trinuclear
platinum compounds that exhibit a different spectrum of cytostatic
activity including activity in tumor cells resistant to cisplatin (10).
It is therefore of great interest to understand details of molecular
mechanisms underlying the biological efficacy of these new compounds,
in particular how these compounds affect double-helical DNA.
Several recent papers have demonstrated unique DNA binding modes
of these bifunctional polynuclear platinum compounds (11-16). We have
shown (11, 14) that the compounds of general formula [{trans-PtCl(NH3)2}H2N(CH2)nNH2]Cl2
(trans-bisPt(n); n = 2-6; Fig. 1)
preferentially form in DNA interstrand cross-links (~80%), and as a
consequence of the global (random) modification of natural, high
molecular mass DNA by these dinuclear platinum compounds, the
conformation of this biomacromolecule is altered in a way that is
distinctly different from the modifications by mononuclear cisplatin.
In these formally bifunctional DNA binding dinuclear platinum agents,
two monofunctional platinum(II) spheres with the single chloride
leaving group on each platinum are linked by a variable length diamine
chain so that the leaving chloride ligands are trans to the
linker. Interestingly, varying the length of the linker may affect the
distance and spatial configuration of the reactive chloride groups in
these dinuclear compounds, hence also their DNA binding mode and
consequently biological effect. Importantly, the observation that these
dinuclear compounds preferentially form in DNA interstrand cross-links
is also in marked contrast to cisplatin, which forms as major DNA
adduct intrastrand cross-links between neighboring purine residues, and the interstrand cross-links only represent minor DNA lesions (~6%; Refs. 17 and 18). In the present work we continue to investigate DNA
interactions of trans-bisPt complexes in cell-free medium to
address further fundamental questions about the mechanism of antitumor
activity of this novel class of platinum drugs. In a previous report
(19), using an indirect assay employing exonuclease digestion of the
DNA fragment globally modified only by one trans-bisPt complex (having n = 4), some sites in DNA involved in
the interstrand cross-links have been already suggested. However, no
systematic study on sequence specificity of these lesions including the
effect of the length of the diamine linker has been performed.
Therefore, first, we examined in detail which sites are preferentially
involved in the major adducts of these dinuclear platinum
compounds with particular attention paid to the effect of the length of
their diamine linker. In addition, we also studied how major adducts of
trans-bisPt compounds affect local conformation of DNA in
particular bending and unwinding.
Some structures altered by platinum adducts, such as bending and
unwinding attract various damaged DNA binding proteins (for instance
those containing high mobility group (HMG) domain; Refs. 20-22). This
binding of these proteins has been postulated to mediate the antitumor
properties of the platinum drugs (23). Therefore, in addition to
examining the structural alterations induced in DNA by the adducts of
trans-bisPt compounds we also investigated in the present
work how these adducts are recognized by HMG1 protein.
 |
EXPERIMENTAL PROCEDURES |
Chemicals--
trans-bisPt(2),
trans-bisPt(4), and trans-bisPt(6) (see Fig.
1A) were prepared as described previously (24). The monoaqua species were generated from trans-bisPt complexes (0.5 mM) by the addition of 0.95 molecular equivalent of
AgNO3 in 10 mM NaClO4 at 37 °C
for 24 h in the dark. The AgCl precipitate was removed by
centrifugation. The synthetic oligodeoxyribonucleotides (see Fig.
1B) were synthesized and purified as described previously (25). HMG1 protein was a generous gift of Dr. M. Stros from the
Institute of Biophysics (Brno, Czech Republic); it was isolated from
calf thymus under nondenaturing conditions and purified and stored as
described previously (26, 27). T4 DNA ligase and T4 polynucleotide
kinase were purchased from New England Biolabs (Beverly, MA).
Acrylamide, bis(acrylamide), urea, and NaCN were from Merck KgaA
(Darmstadt, Germany). Dimethyl sulfate (DMS), KMnO4,
diethyl pyrocarbonate (DEPC), KBr, and KHSO5 were from Sigma. [
-32P]ATP was from Amersham Pharmacia Biotech.
Platinations of Oligonucleotides--
The single-stranded
oligonucleotides (the top strands of the duplexes in Fig. 1B
except d(TGGT)/d(ACCA)) were reacted in stoichiometric amounts with
monoaqua derivatives of trans-bisPt complexes. The platinated oligonucleotides were repurified by ion exchange fast protein liquid chromatography (FPLC). It was verified by platinum flameless atomic absorption spectrophotometry and by the measurements of the optical density that the modified oligonucleotides contained two
platinum atoms. It was also verified using DMS footprinting of platinum
on DNA (17, 28, 29) that in the platinated top strands of all duplexes
the N-7 position of single guanine residue was not accessible for
reaction with DMS. Briefly, platinated and nonmodified top strands
(5'-end-labeled with 32P) were reacted with DMS. DMS
methylates the N-7 position of G residues in DNA, producing alkali
labile sites (30). However, if N-7 is coordinated to platinum, it
cannot be methylated. The oligonucleotides were then treated with hot
piperidine and analyzed by denaturing 24% polyacrylamide gel
electrophoresis. For the nonmodified oligonucleotides, shortened
fragments caused by the cleavage of the strand at one methylated G were
observed in the gel. However, no such bands were detected for the
oligonucleotides modified by trans-bisPt complexes. These
results indicate that one trans-bisPt molecule was
coordinated to single G in the top strands of all duplexes. The
platinated top strands were allowed to anneal with nonplatinated
complementary strands (the bottom strands in Fig.
1B) in 0.1 M NaClO4. The resulting
products were analyzed by FPLC in an alkaline gradient. Using this
denaturing gradient, noninterstrand cross-linked strands were eluted as
a 20-23-nucleotide single strand, whereas the interstrand cross-linked strands were eluted later in a single peak as a higher molecular mass
species. This single peak was only collected so that the samples of the
interstrand cross-linked duplexes contained no single-stranded
molecules. Alternatively, the products were separated on 12%
polyacrylamide/8 M urea denaturing gel, and the bands
corresponding to interstrand cross-linked duplexes were analyzed by
densitometry or were cut off from the gel, eluted, precipitated by
ethanol, and dissolved in 50 mM NaCl. Both procedures of
the purification of interstrand cross-linked duplexes provided the
products whose subsequent analysis (see below) gave identical results.
FPLC purification and flameless atomic absorption spectrophotometry
measurements were carried out on an Amersham Pharmacia Biotech FPLC
System with MonoQ HR 5/5 column and a Unicam 939 AA spectrometer
equipped with a graphite furnace, respectively. The duplexes
d(TGGT)/d(ACCA) (Fig. 1B) containing single, 1,2-d(GpG)
intrastrand cross-link of trans-bisPt or cisplatin in the
top strand were prepared as described (17, 28, 29).
Chemical Modifications--
The modification by
KMnO4, DEPC, and KBr/KHSO5 were performed as
described previously (31-34). The strands of the duplexes were
5'-end-labeled with [
-32P]ATP. In the case of the
platinated oligonucleotides, the platinum complex was removed after
reaction of the DNA with the probe by incubation with 0.2 M
NaCN (alkaline pH) at 45 °C for 10 h in the dark.
Ligation and Electrophoresis of
Oligonucleotides--
Nonplatinated single strands (top
strands in Fig. 1B) and the duplexes containing a
unique interstrand cross-link were 5'-end-labeled with
[
-32P]ATP by using T4 polynucleotide kinase. Then the
single-stranded, nonplatinated oligonucleotides were annealed with
their phosphorylated complementary strands. Nonplatinated or cross-link
containing duplexes were allowed to react with T4 DNA ligase. The
resulting samples along with ligated nonplatinated duplexes were
subsequently examined on 8% native polyacrylamide
(mono:bis(acrylamide) ratio = 29:1) electrophoresis gels. Other
details of these experiments were as described in previously published
papers (35, 36). Some ligation products were also used as the DNA
probes in the studies of the recognition of DNA adducts of
trans-bisPt compounds by HMG1 proteins. For these
experiments the double-stranded oligonucleotides 105 base pairs (bp) in
length (containing five identical 21-bp oligonucleotide units
d(TGTCT)/d(AGACA) (21) shown in Fig. 1B) were eluted from
native polyacrylamide gels, precipitated by ethanol, and resuspended in
10 mM Tris-HCl/1 mM EDTA buffer, pH 7.4, to 5000 cpm/ml. For quantitation, the gel was stained with 0.5 mg of
ethidium bromide/ml, and the amount of oligonucleotide duplex was
determined in comparison with a known quantity of
standard double-stranded oligonucleotide using a SepraScan 2001 image processing system for gel quantitation (ISS-Enprotech).
Gel Mobility Shift Assay--
The study of HMG1-DNA binding
complexes was carried out as described (37) with small modifications. 3 nM radiolabeled oligonucleotide probes 105 bp in length
(concentration is related to the content of the 105-bp duplex), either
nonmodified or containing the cross-link, were incubated for 15 min at
0 °C (ice bath) in the presence of 50 or 100 nM HMG1
protein and 0.2 mg of nonlabeled, sonicated calf thymus DNA/ml in the
binding buffer (150 mM NaCl, 10 mM
MgCl2, 20% glycerol, 0.2 mg of bovine serum albunim/ml, 10 mM HEPES-OH, pH 7.9, and 1 mM dithiothreitol)
in a final volume of 10 µl. The protein-DNA complexes were then
resolved on a 7% polyacrylamide gel (29:1
acrylamide/N,N'-methylene-bis(acrylamide)). The
samples were electrophoresed at 4 °C using the electrophoresis
buffer containing 0.045 M Tris borate and 1 mM
EDTA, pH 8.0, and autoradiographed.
 |
RESULTS |
Sequence Specificity of Interstrand Cross-linking--
We
demonstrated in our preceding papers (14) that the preferential DNA
binding sites of trans-bisPt compounds are G residues and
that the major DNA adducts of these dinuclear platinum complexes are
interstrand cross-links. In these cross-links the platinated sites are
separated by one or more base pairs. Bifunctional dinuclear platinum
complexes must bind to DNA first through one end of the dinuclear unit.
In this first step of binding, the kinetic preferences are similar to
those of mononuclear species, i.e. they coordinate preferentially to N-7 atoms of G residues. The array of adducts becomes, however, different upon the coordination of the second platinum unit (19). Considering these facts we have designed a series
of synthetic oligodeoxyribonucleotide duplexes 1,2, 1,3, and 1,4, whose
sequences are shown in Fig. 1B. The
pyrimidine-rich top strands of these duplexes only contained one G in
the center (bold type in Fig. 1B). These top
strands were modified by trans-bisPt complexes so that they
contained a single monofunctional adduct of these platinum complexes at
this central G site. The duplexes were also designed in such a way that
their bottom (complementary) strands contained G in different positions
symmetrically to the single central cytosine (complementary to the
platinated G in the top strand). In this way, the G residue in the top
strand with the monofunctionally attached trans-bisPt
complex could close to 1,2, 1,3, or 1,4 GG interstrand cross-links in
the duplex 1,2, 1,3, or 1,4, respectively. The 1,2 interstrand
cross-link is formed between G sites in neighboring base pairs, whereas
in 1,3 and 1,4 interstrand cross-links, the platinated G sites are
separated by one or two base pairs, respectively. G sites in the bottom strands involved in these interstrand cross-links are also in bold type in Fig. 1B. The nucleotide sequences of
the duplexes were also designed in the way that these interstrand
cross-links could close to G in the bottom strands located on both
sides of the central C residue, i.e. in the 5'
5' or 3'
3' direction. The orientation of the interstrand cross-link in the
5'
5' or 3'
3' direction can be explained with the aid of the
sequence of the duplex 1,3. For instance, the 1,3 GG interstrand
cross-link oriented in the 5'
5' direction is that formed in the
duplex 1,3 between the central G in the top strand and G in position 10 in the bottom strand, whereas the same cross-link oriented in the 3'
3' direction is that between the central G in the top strand and G
in position 14 in the bottom strand.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
Structures of dinuclear platinum complexes
(A) and sequences of the synthetic
oligodeoxyribonucleotides used in the present study with their
abbreviations (B). The top and
bottom strands of each pair are designated top and bottom,
respectively, in the text. The bold letter in the top
strands of all duplexes except d(TGGT)/d(ACCG) indicates the location
of the monofunctional adduct of trans-bisPt complexes formed
before interstrand cross-linking reaction in the way also described in
the experimental section. The bold letters in the top strand
of d(TGGT)/d(ACCA) duplex indicate the location of the intrastrand
cross-link after modification of the oligonucleotides by
trans-bisPt complexes or cisplatin in the way described
under "Experimental Procedures." For the duplex 1,3, the numbering
of the nucleotide residues in the bottom strand is also shown.
|
|
The monoadducted top strands of the duplexes 1,2, 1,3, and 1,4 were
hybridized with their complementary strands, and the hybrids were
incubated in 0.1 M NaClO4 at 37 °C. The
aliquots were withdrawn at various time intervals and analyzed by gel
electrophoresis under denaturing conditions. As shown in Fig.
2A for the duplex 1,2 modified
by trans-bisPt(4), one band was only observed for the
non-cross-linked duplex. The subsequent incubation resulted in new
bands migrating markedly more slowly. Their intensity increased with
the incubation time with a concomitant decrease in the intensity of the
band corresponding to the non-cross-linked duplex. This observation can
be interpreted to mean that interstrand cross-links were formed. From
the ratio of the sum of intensities of all bands corresponding to
cross-linked duplexes and the sum of intensities of all bands, the
percentage of interstrand cross-links was calculated (Fig.
2B). The half-time of this interstrand cross-linking
reaction in the duplex 1,3 was about 1 h. A similar result was
obtained for the duplex 1,4, whereas the half-time found for the duplex 1,2 was markedly higher. The kinetics of the interstrand cross-linking reactions in all three duplexes were approximately the same and independent of the linker length of the trans-bisPt complex
(n = 2, 4, or 6) (not shown).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Kinetics of DNA interstrand cross-link
formation by trans-bisPt(4) complex. The
duplexes 1,2, 1,3, and 1,4 were formed by mixing their bottom strand
with the complementary upper strand uniquely monoadducted by
trans-bisPt(4) at the central G residue at 37 °C.
A, autoradiogram of a 12% polyacrylamide/8 M
urea denaturing gel of the duplex 1,2 whose bottom strand was
32P end-labeled. The cross-linking reaction was stopped by
adjusting the NaOH concentration to 10 mM and cooling the
samples to 70 °C. inter designates bands corresponding
to the interstrand cross-linked fraction (see also the text).
Lane 1, 0 h; lane 2, 2 h; lane
3, 4 h; lane 4, 17.5 h; lane 5,
24 h; lane 6, 48 h. B, the percentage
of interstrand cross-linking in the duplexes 1,2 ( ), 1,3 ( ), and
1,4 ( ) by trans-bisPt(4) calculated from the ratio of the
sum of the intensities of the bands corresponding to the fragments
containing an interstrand cross-link to the sum of the intensities of
all bands (corresponding to the non-cross-linked and the cross-linked
oligonucleotides).
|
|
The cross-linking reactions in the duplexes 1,2, 1,3, and 1,4 resulted
in only one band or single peak in the FPLC profile designated as
inter in Fig. 2A (shown for the duplex 1,2 and
trans-bisPt(4)). After a 24-h reaction period, the bands or
FPLC peaks corresponding to the interstrand cross-linked duplexes were
cut off from the gel or collected after FPLC separation, respectively,
and the duplexes were isolated (eluted from the bands and precipitated or only precipitated from the FPLC fractions) and further characterized by Maxam-Gilbert footprinting (28, 31, 38).
The samples of the 1,2, 1,3, and 1,4 interstrand duplexes cross-linked
by either trans-bisPt(2, 4, 6) in which the upper strand was
only 5'-end labeled with 32P were reacted with DMS, which
does not react with platinated G because the N-7 position is no longer
accessible (28, 31, 38). The adducts were removed by NaCN (28, 39), and
then the sample was treated with piperidine. In the nonplatinated
duplexes, the central G in the top strands was reactive with DMS (not
shown). It was no longer reactive in all three cross-linked duplexes. This observation confirms that the unique G in the upper strands remained platinated and was involved in the interstrand cross-link contained in the single fraction of interstrand cross-linked duplexes (28, 31, 38).
In further studies the 1,2, 1,3, and 1,4 interstrand duplexes in which
the bottom strand was 5'-end labeled with 32P were
examined. Results of typical experiments, in which the locations of
nucleotides involved in the interstrand cross-link of
trans-bisPt(4) formed in the duplexes 1,2, 1,3, or 1,4 were determined, are shown in Fig. 3. The
interstrand cross-linked duplexes were reacted with DMS. Then these
samples were further treated with NaCN to remove the adducts and
finally also with piperidine. The treatment with piperidine of the
control, nonplatinated duplex resulted in the cleavage at all G sites
in the bottom strand (Fig. 3, no Pt lanes). If the
cross-linked duplexes treated with DMS and subsequently NaCN were
cleaved (Fig. 3, Pt/NaCN lanes), the bands corresponding to
all G residues were observed except G residues marked by an
arrow in Fig. 3. This result proves that these G residues
were platinated and involved in the interstrand cross-link of the
trans-bisPt(4) compound. Identical results of these
footprinting experiments were obtained if trans-bisPt(2) or
trans-bisPt(6) were used to cross-link the duplexes 1,2, 1,3, or 1,4. It implies that the interstrand adducts formed by the trans-bisPt complexes were GG interstrand adducts formed at
the G site in the bottom strand exclusively in the direction to its 5'
end (oriented in the 5'
5' direction) and that the sites of
interstrand cross-linking by trans-bisPt complexes were not substantially affected by the length of the linker chain.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 3.
Maxam-Gilbert footprinting experiments.
Autoradiograms of denaturing 24% polyacrylamide/8 M urea
gels of the products of the reaction between DMS (G-specific reactions)
and the duplexes 1,2 (left), 1,3 (center), and
1,4 (right) either nonmodified or containing an interstrand
cross-link of trans-bisPt(4). The bottom strands of the
duplexes were 5'-end labeled. No Pt lanes, nonplatinated
duplex; Pt/CN lanes, the duplex
containing interstrand cross-link with platinum removed by NaCN after
modification by DMS. For other details, see the text.
|
|
Chemical Probes of DNA Conformation--
Because 1,2 interstrand
cross-links represent only less frequent lesions formed in DNA by
trans-bisPt complexes, further studies of the present work
were focused mainly on the major 1,3 interstrand cross-link. The
oligonucleotide duplexes containing single 1,3 interstrand cross-link
between G residues oriented in the 5'
5' direction were further
analyzed by chemical probes of DNA conformation. The interstrand
cross-linked duplexes were treated with several chemical agents that
are used as tools for monitoring the existence of conformations other
than canonical B-DNA. These agents include KMnO4, DEPC, and
bromine. They react preferentially with single-stranded DNA and
distorted double-stranded DNA (31-34, 40). In the following text the
analysis of the duplex d(TGTCT)/d(AGACA) (21) (see Fig. 1B
for its sequence) containing 1,3 interstrand cross-link of
trans-bisPt(4) is demonstrated as a general example.
KMnO4 is hyperreactive with thymine residues in
single-stranded nucleic acids and in distorted DNA as compared with
B-DNA (32, 34, 41, 42). KMnO4 reacted with no residue
within the nonplatinated duplex (Fig.
4A, lane ds). All T
residues were strongly reactive in the nonplatinated single-stranded
top oligonucleotide (Fig. 4A, lane ss). The
interstrand cross-linked duplex showed strong reactivity of the 5' T
residue adjacent to the adduct (Fig. 4A, lane
dsPt). A somewhat weaker reactivity was also observed for the
second 5' T and the 3' T adjacent to the platinated G involved in the
cross-link.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 4.
Chemical probes of DNA conformation.
Piperidine-induced specific strand cleavage at
KMnO4-modified (A), DEPC-modified
(B), and KBr/KHSO5-modified (C and
D) bases in the duplex d(TGTCT)/d(AGACA)(21) nonplatinated
or containing single 1,3 interstrand cross-link of
trans-bisPt(4). The oligomers were 5'-end labeled at their
top or bottom strands. A, KMnO4, only top strand
end labeled. Lane ss, the nonplatinated top strand;
lane ds, the nonplatinated duplex; lane dsPt, the
duplex interstrand cross-linked by trans-bisPt(4);
lane G, a Maxam-Gilbert specific reaction for the
nonplatinated duplex. B, DEPC, only bottom strand end
labeled. Lane ss, the nonplatinated top strand; lane
ds, the nonplatinated duplex; lane dsPt, the duplex
interstrand cross-linked by trans-bisPt(4); lane
C+T, a Maxam-Gilbert specific reaction for the nonplatinated
duplex. C, KBr/KHSO5, only top strand end
labeled. Lane ss, the nonplatinated top strand; lane
ds, the nonplatinated duplex; lane dsPt, the duplex
interstrand cross-linked by trans-bisPt(4); lane
G and C+T, Maxam-Gilbert specific reactions for the
nonplatinated duplex. D, KBr/KHSO5, only bottom
strand end labeled. Lane ss, the nonplatinated top strand;
lane ds, the nonplatinated duplex; lane dsPt, the
duplex interstrand cross-linked by trans-bisPt(4);
lane C+T and G, Maxam-Gilbert specific reactions
for the nonplatinated duplex. E, summary of the reactivity
of chemical probes; , , and designate strong, medium and weak
reactivity, respectively.
|
|
DEPC carbetoxylates purines at the N-7 position. It is hyperreactive
with unpaired and distorted adenine residues in DNA and with
left-handed Z-DNA (32, 34, 43, 44). A and G residues within the
nonplatinated single-stranded oligonucleotide (top and bottom) readily
reacted with DEPC (shown for the bottom strand in Fig. 4B,
lane ss). No reactivity of A and G residues was observed within the nonplatinated duplex (shown for the bottom strand in Fig.
4B, lane ds). Within the double-stranded
oligonucleotide containing the interstrand cross-link, three base
residues in the bottom strand became reactive (Fig. 4B,
lane dsPt). These are readily identified as the three A
residues complementary to the reactive T residues of the top strand.
Importantly, A residues complementary to strongly reactive T residues
also reacted with DEPC strongly, whereas those A residues complementary
to more weakly reactive T residues also reacted with DEPC, only more weakly.
Bromination of C residues and formation of piperidine-labile sites are
observed when two simple salts, KBr and KHSO5, are allowed
to react with single-stranded or distorted double-stranded oligonucleotides (33). The reaction proceeds via generation of
Br2 in situ, which reacts selectively with the
5,6 double bond to add Br and OH, respectively. H2O is then
eliminated to give 5-bromodeoxycytidine, which is susceptible to
depyrimidination under basic conditions. All C residues within the
nonplatinated single-stranded top or bottom strands of the
d(TTGTCT)/d(AGACAA) duplex were strongly reactive (Fig. 4, C
and D, lanes ss). No reactivity of these residues
was observed within the nonplatinated duplex (Fig. 4, C and
D, lanes ds). Within the double-stranded duplex
containing the cross-link no C residue in the top strand, including
that complementary to the G residue in the bottom strand involved in
the cross-link was reactive (Fig. 4C, lane dsPt). In contrast, the only C residue in the bottom strand (complementary to
the platinated G residue in the top strand) was strongly reactive (Fig.
4D, lane dsPt).
The results of the analysis of the d(TGTCT)/d(AGACA) (21) duplex
containing 1,3 GG interstrand cross-link of trans-bisPt(4) by chemical probes are summarized in Fig. 4E. Importantly,
identical results as demonstrated in Fig. 4 were obtained also for the
duplex containing the cross-link of trans-bisPt(2) and (6) compounds.
DNA Unwinding and Bending--
Among the alterations of secondary
and tertiary structure of DNA to which it may be subject, the role of
intrinsic bending and unwinding of DNA is increasingly recognized as
being of potential importance in regulating replication and
transcription functions through specific DNA-protein interactions. For
DNA adducts of cisplatin, the structural details responsible for
bending and subsequent protein recognition have recently been
elucidated (21, 23). Given the recent advances in our understanding of
the structural basis for the bending of DNA caused by cisplatin
cross-links, it is of considerable interest to examine how major DNA
adducts of trans-bisPt compounds (interstrand cross-links)
affect conformational properties of DNA such as bending and unwinding.
In this work we further performed studies on the bending and unwinding
induced by single, site-specific 1,3 GG interstrand cross-link of
trans-bisPt(4) formed in the oligodeoxyribonucleotide
duplexes using electrophoretic retardation as a quantitative measure of
the extent of planar curvature.
The oligodeoxyribonucleotide duplexes d(TGTCT)/d(AGACA) (20-23)
(20-23 bp, for their sequence see Fig. 1B) were used for
the bending and unwinding studies of the present work. All sequences were designed to leave a 1-nucleotide overhang at their 5'-ends in
double-stranded form. These overhangs facilitate polymerization of the
monomeric oligonucleotide duplexes by T4 DNA ligase in only one
orientation and maintain a constant interadduct distance throughout the
resulting multimer. Autoradiograms of electrophoresis gels revealing
resolution of the ligation products of nonplatinated 20-23-bp duplexes
or containing a unique 1,3 GG interstrand cross-link of
trans-bisPt(4) are shown in Fig.
5. A small but significant retardation
was observed for the multimers of all platinated duplexes. Decreased
gel electrophoretic mobility may result from a decrease in the DNA
end-to-end distance (45). Various platinum(II) complexes have been
shown to form DNA adducts that decrease gel mobility of DNA fragments
because of either stable curvature of the helix axis or increased
isotropic flexibility (31, 36, 46-48). DNA multimers of identical
length and number of stable bend units, but with differently phased
bends, have different end-to-end distances. The DNA bends of a multimer
must therefore be spaced evenly and phased with the DNA helical repeat
to add constructively. Such constructively phased bends add in plane,
yielding short end-to-end distances and the most retarded gel
migration. In other words, gel electrophoresis of multimers of
oligonucleotide duplexes that only differ in length and contain a
stable curvature induced by the same platinum adduct should exhibit a
phase effect, i.e. the maximum retardation should be
observed for the multimers having the bends in phase with helix screw.
In contrast, the normal electrophoretic mobility should be observed for
the multimers having the bends separated by a half-integral number of
DNA turns. The K factor is defined as the ratio of
calculated to actual length. The calculated length is based on a
multimer's mobility and is obtained from a calibration curve
constructed from the mobilities of nonplatinated multimers. The
variation of the K factor versus sequence length obtained for multimers of the duplexes 20-23 bp long and containing the unique 1,3 GG interstrand cross-link of trans-bisPt(4)
is shown in Fig. 6A. Maximum
retardation was observed for the 21-bp cross-linked duplex. The 20- and
22-bp curves exhibited smaller but different slopes. This observation
suggests that the natural 10.5-bp repeat of B-DNA and that of DNA
perturbed by the interstrand cross-link of trans-bisPt(4)
are slightly different as a consequence of DNA unwinding (49). In other
words, this asymmetry is consistent with DNA unwinding due the
formation of the interstrand cross-link of trans-bisPt(4)
compound.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 5.
Autoradiogram of the ligation products of
double-stranded oligonucleotides d(TGTCT)/d(AGACA)(20-23). The
duplexes contained a unique 1,3 interstrand cross-link formed by
trans-bisPt(4) between central G in the top strand and G in
the bottom strand oriented in the 5' 5' direction (see the text).
The ligation products were separated on an 8% polyacrylamide gel
(Pt lanes). no Pt lanes, nonplatinated
oligomers.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of the mobility of the ligation
products of interstrand cross-linked duplexes d(TGTCT)/d(AGACA)(20-23)
in an 8% polyacrylamide gel. A, plots showing the
relative mobility K versus sequence length curves for the
oligomers d(TGTCT)/d(AGACA)(20-23) containing a unique 1,3 interstrand
cross-link formed by trans-bisPt(4) between central G in the top strand
and G in the bottom strand oriented in the 5' 5' direction (see the
text) denoted respectively as 20, 21,
22, and 23. B, plots showing the
relative mobility K versus interadduct distance in bp for
the oligomers d(TGTCT)/d(AGACA)(20-23) interstrand cross-linked by
trans-bisPt(4) with a total length of 150 bp ( ) and 170 bp ( ).
The experimental points represent the averages of three
independent electrophoresis experiments. The curves
represent the best fit of these experimental points to the equation
K = ad2 + bd + c (49).
|
|
The exact helical repeat of the interstrand cross-linked duplex and
from it the unwinding angle were calculated by interpolation with the
use of the K versus interadduct distance curve as described in the previous paper for intrastrand adducts of cisplatin (49). The
maximum of these curves constructed for the interstrand cross-linked duplexes with a total length of 150 bp (Fig. 6B) were
determined to be 21.25 ± 0.04. Total sequence lengths other than
150 bp were examined and gave identical results (shown for duplexes
with a total length 170 bp in Fig. 6B). To convert the
interadduct distance in base pairs corresponding to the curve maximum
into a duplex unwinding angle in degrees, the value is compared with
that of the helical repeat of B-DNA, which is 10.5 ± 0.05 bp (50,
51). The difference between the helical repeat of B-DNA and DNA
containing the 1,3 interstrand cross-link of trans-bisPt(4),
therefore, is [(21.25 ± 0.04)
2(10.5 ± 0.05)] = 0.25 ± 0.09 bp. There are 360°/10.5 bp, so the DNA unwinding
caused by one 1,3 interstrand adduct of trans-bisPt(4) is
9 ± 3°. This unwinding angle is very small, in contrast to that
found for example for 1,2 GG interstrand cross-link of cisplatin using
the same experimental procedure (79° (52) or ~90° (48)).
The evaluation of the relationship between interadduct distance and
phasing for self-ligated multimers composed of the identical number of
monomeric duplexes (bend units) resulted in a bell-shaped pattern (Fig.
6B) characteristic for bending (31, 36, 46-48, 52). The
quantitation of the bend angle of the 1,3 interstrand cross-link of
trans-bisPt(4) was performed in the way described previously
(31, 36, 46-48, 52) utilizing the following empirical equation.
|
(Eq. 1)
|
where L represents the length of a particular oligomer
with relative mobility K, and RC represents the
curvature relative to a DNA bending induced at the tract of A residues
(A tract) (46, 53). Application of Equation 1 to the 105-, 126-, or 168-bp multimers of the 21-bp oligomer containing the single 1,3 interstrand cross-link of trans-bisPt(4) leads to a mean
curvature of 0.25, relative to the A tract. The average bend angle per
helix turn can be calculated by multiplying the relative curvature by the absolute value of the A tract bend (20°; Refs. 36, 46, 53, and
54). The results indicate that the bend induced by the 1,3 GG
interstrand cross-link of trans-bisPt(4) is only about 10°. Other details of the calculations of the unwinding and bending angles are given in the previously published papers (31, 36, 46-48,
52). Importantly, similarly small unwinding and bending angles were
yielded by the analysis of 1,3 GG interstrand cross-links formed by
other two trans-bisPt compounds (n = 2 and
6) (not shown). Also importantly, small values of bending and unwinding
angles similar to those deduced from the experiments shown in Figs. 5 and 6 were produced by the 1,4 GG interstrand cross-links formed by all
three trans-bisPt(2, 4 or 6) compounds as well.
Recognition by HMG1 Protein--
The bending of the helix axis
induced by DNA intrastrand and interstrand cross-links of cisplatin and
the altered structure attract HMG and other proteins (20, 22). This
binding of HMG domain proteins to cisplatin-modified DNA has been
postulated to mediate the antitumor properties of this drug (21, 23). Because bifunctional trans-bisPt and other dinuclear
compounds exhibit antitumor activity different from cisplatin, it was
of considerable interest to examine how the adducts of
trans-bisPt compounds are recognized by HMG domain proteins.
The interactions of the HMG1 protein, which is the prototypical member
of a family of these proteins, with major DNA interstrand cross-links
of trans-bisPt compounds were investigated by means of gel
mobility shift experiments (Fig. 7). In
these experiments, the duplex d(TGTCT)/d(AGACA) (21) was modified so
that it contained a single, defined 1,3 GG interstrand adduct. These
duplexes were radiolabeled and ligated to multimers. After the ligation
reaction, the DNA probes composed of five duplex oligonucleotide units
were purified. Thus, these 105-bp DNA probes contained five identical
interstrand cross-links regularly separated by identical 21-bp
segments. Similar DNA probes of such length were already used in the
previous work (22, 55) to demonstrate a specific binding of the DNA
damage recognition proteins to DNA adducts of cisplatin. These
proteins, identified as the HMG domain proteins (56), were found to
bind the probes similar to those used in this work, which were at least
88 or more bp long (55).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
Electrophoretic gel mobility shift
assay. Double-stranded DNA fragments, 105 bp in length, were
prepared from the 5'-end labeled duplexes d(TGTCT)/d(AGACA) (21) or
d(TGGT)/d(ACCA). The duplexes were either nonmodified (lanes
1 and 2) or contained the platinum cross-link
(lanes 3-12), the 1,3 interstrand cross-link of
trans-bisPt(4) (lanes 5-8), and 1,2 d(GpG)
intrastrand cross-links of cisplatin (lanes 3 and
4) or trans-bisPt(4) (lanes 9-12).
These 105-bp DNA probes at the concentration of 3 nM were
incubated in absence (lanes 1, 3, 5,
and 9) or presence of 1.5 ng (lanes 4,
6, and 10), 4.5 ng (lanes 7 and
11) or 7.5 ng (lanes 2, 8, and
12) of HMG1 protein. Nonmodified, nonlabeled calf thymus DNA
was used as a nonspecific competitor at the concentration of 0.2 mg/ml
(lanes 1-12). For other details, see the text.
|
|
The binding of the HMG1 protein to these DNA probes in the presence of
2,000-fold excess of nonlabeled nonspecific calf thymus competitor DNA
was detected by retardation of the migration of the radiolabeled 105-bp
probe through the gel (22, 55, 56) (Fig. 7). There is a specific
binding of the HMG1 protein to the DNA probe containing the 1,3 GG
interstrand cross-link of trans-bisPt(4) as evidenced by the
presence of a more slowly migrating band that is not seen for the same
duplex analyzed in the absence of the HMG1 protein (Fig. 7, lanes
6-8). To compare the binding affinity of the HMG1 protein to the
1,3 GG interstrand cross-link of trans-bisPt compounds and
to the 1,2-(GpG) intrastrand cross-link of cisplatin, a DNA probe was
also prepared so that it contained this cisplatin adduct. This probe
was prepared by ligation of five 21-bp oligonucleotide units
(d(TGGT)/d(ACCA); see Fig. 1B for its sequence), each
containing the single central sequence d(GpG)/d(CpC) at which the
intrastrand cross-link of cisplatin was formed so that this DNA probe
was also 105 bp in length. As expected, this radiolabeled intrastrand cross-linked probe readily bound the HMG1 protein in the presence of
2,000-fold excess of nonlabeled nonspecific calf thymus competitor DNA
(Fig. 7, lane 4). The densitometric evaluation of the bands in Fig. 7 showed that the affinity of HMG1 protein to the 1,3 GG
interstrand cross-link of trans-bisPt(4) was approximately 1 order of magnitude lower. Again, identical results were obtained in the
experiments using the same DNA probe, but containing the 1,3 interstrand cross-link of trans-bisPt(2 and 6) or 1,4 interstrand cross-link of all three trans-bisPt compounds
tested in the present work (not shown). Also importantly, no binding of
the protein occurred under identical experimental conditions in the
cases where the same 105-bp DNA probes were not platinated (Fig. 7, lane 2).
trans-bisPt compounds may also form as a minor DNA adduct
intrastrand cross-link between two neighboring G residues (1,2 (GpG) intrastrand cross-link), which is the direct analogue of the major cisplatin adduct (19). Recently, we described a structural analysis of
this intrastrand cross-link of trans-bisPt compounds (12). The formation of this adduct resulted in conformational alterations distinctly different from those produced by the same adduct of cisplatin. One of the major differences comprised a flexible
nondirectional bend in contrast to the same adduct of cisplatin, which
produces in DNA a stable directional curvature (bends helix axis toward major groove by 30-60°; Refs. 36 and 57-59). It has been predicted on the basis of this result (12) that this intrastrand cross-link of
trans-bisPt complex should be recognized by HMG domain
proteins markedly less efficiently than the same cross-link formed in
DNA by cisplatin. To determine how the 1,2-(GpG) intrastrand
cross-links of trans-bisPt compounds are recognized by HMG
domain proteins, we have further prepared 105-bp DNA probes that
contained five identical GG intrastrand cross-links of either
trans-bisPt(2, 4, or 6) regularly separated by identical
21-bp segments. The results demonstrating affinity of the DNA probe
containing 1,2-(GpG) intrastrand cross-links of
trans-bisPt(4) to HMG1 protein are illustrated in Fig. 7
(lanes 10-12). No more slowly migrating band indicating the
specific binding of the HMG1 protein to the DNA probe containing the
1,2 d(GpG) intrastrand cross-link of trans-bisPt(4) was
noticed even at the highest concentrations of HMG1 protein used in
these experiments. The identical results were obtained with the probe
containing these adducts of trans-bisPt(2 or 6) (not shown).
From these results and the results demonstrating the affinity of HMG1
protein to the major adduct of trans-bisPt compounds, it is
clear that the DNA intrastrand adducts of trans-bisPt compounds are not recognized by HMG1 protein or that their affinity to
this protein is markedly lower than that of intrastrand or interstrand
cross-links of cisplatin.
 |
DISCUSSION |
The sequence specificity of interstrand cross-link formation in
DNA by trans-bisPt compounds has been assayed in the present work by Maxam-Gilbert footprinting. The experiments presented here
(Figs. 2B and 3) clearly demonstrate that preferential DNA binding sites in these lesions are G residues in the base pairs separated by at least one another base pair. The cross-links between G
residues in neighboring base pairs (1,2 interstrand cross-links) are
formed with a pronouncedly slower rate (Fig. 2B) so that it is reasonable to suggest that 1,2 GG interstrand cross-links represent less frequent adducts of trans-bisPt compounds. Thus, the
formation of long range cross-links by trans-bisPt compounds
proposed in earlier papers (14, 19) and hence the ability of these
dinuclear platinum compounds to target larger sequences of DNA has been confirmed in this study. Our analysis has also demonstrated that the
sites involved in DNA interstrand cross-linking by
trans-bisPt compounds are essentially identical for
n = 2, 4, and 6 so that the length of the diamine
bridge linking the two platinum units does not appear to be a
substantial factor affecting DNA interstrand cross-linking by these
dinuclear platinum compounds. Importantly, the results of the present
work (Fig. 3) have also confirmed under competitive conditions that the
interstrand cross-links of trans-bisPt complexes are
preferentially formed in the 5'
5' direction. The reasons for this
preference in the orientation of DNA interstrand cross-links of
trans-bisPt compounds are unknown. Interestingly, the same
preference in the orientation of interstrand cross-links is also
observed for the geometric isomers of trans-bisPt compounds, [{cis-PtCl(NH3)2}H2N(CH2)nNH2]Cl2,
n = 4,6 (which have left chloride ligands
cis to the linker) (15) so that this feature of the
interstrand cross-linking might be common for this class of platinum compounds.
The present paper also describes the conformational distortion induced
in DNA by the 1,3 GG interstrand cross-links of trans-bisPt complexes. The bending experiments were carried out with the
double-stranded oligodeoxyribonucleotides d(TGTCT)/d(AGACA) (20-23)
(Fig. 1B) containing the unique interstrand cross-link in
their central sequence. The phasing assay (Figs. 5 and 6) has revealed
that the 1,3 GG interstrand cross-link of trans-bisPt
complexes results only in a very small directional bending of helix
axis (~10°) and duplex unwinding (~9°), and basically the same
result was obtained for the 1,4 GG interstrand cross-link.
Despite these small bending and unwinding effects the major interstrand
cross-links formed by trans-bisPt compounds in the d(TGTCT)/d(AGACA) (21) duplex created a local conformational distortion
revealed by the chemical probes (Fig. 4). This distortion was
nonsymmetrical and extended mainly over four base pairs (Fig. 4E). A careful examination of these results reveals that
mainly base pairs containing pyrimidine bases, two 5' and one 3' to the platinated G in the top strand were distorted. This observation may
reflect the fact that the long range cross-links of bifunctional dinuclear platinum compounds affect DNA in the first approximation almost as two independent monofunctional adducts of mononuclear platinum(II) complexes. It has been shown (25, 60) that
monofunctional adducts of mononuclear platinum(II) complexes also
considerably distort DNA, but in a sequence-dependent
manner. Major extensive distortions in base pairs localized around the
monofunctional adduct of mononuclear platinum(II) complexes at G
residue were observed only if such a platinated G was flanked by
pyrimidine residues. In contrast, no or weak distortions were noticed
using chemical probes if the platinated G was flanked by purine
residues particularly on its 5' site. Thus, if the G residues involved in the 1,3 interstrand cross-link of trans-bisPt complex in
the d(TGTCT)/d(AGACA) duplex are substituted by the same G residues at
which monofunctional adduct of mononuclear platinum(II) complex was
formed, a reactivity pattern of chemical probes similar or identical to
that seen in Fig. 4E is obtained. In other words, the
platinated G residue in the top strand (involved in the interstrand cross-link) is flanked by pyrimidine residues, and hence the base pairs
adjacent to this G residue are distorted. In contrast, the second
platinated G in the bottom strand (involved in the cross-link) is
flanked by purine residues so that in accord with what has been deduced
above the base pairs adjacent to this second platinated G are not
distorted or are distorted much less extensively. That long range
cross-links of trans-bisPt complexes distort duplex similarly as two close but independent monofunctional adducts of
mononuclear platinum(II) complexes is also sustained by the observation
that these long range interstrand cross-links unwind DNA by only
~9°, which is a value close to the unwinding angle produced by
monofunctional adducts of mononuclear platinum(II) complexes (~6°;
Ref. 61). Similarly, no bending of helix axis by these monofunctional
platinum(II) adducts was observed (25), which is again close to the
small values of ~10° found for 1,3 and 1,4 interstrand cross-links
of trans-bisPt compounds in the present work.
Thus the results of the present work indicate that some localized
conformational features of major DNA adducts of antitumor trans-bisPt compounds are similar to those of monofunctional
mononuclear platinum(II) compounds, such as
chlorodiethylenetriamineplatinum(II) chloride [PtCl(dien)]Cl or
[PtCl(NH3)3]Cl, which are clinically ineffective. The chemical probes, which revealed these similarities, allow detecting the sites where the distortion is localized and its
extent, but they do not provide all details about the character or
nature of the distortion. It has been shown (11, 14, 62) with the aid
of various methods of molecular biophysics, such as for instance
circular dichroism of DNA, DNA melting curves, and immunochemical
analysis, that on the other hand several features of conformational
distortions induced in DNA by dinuclear platinum compounds are
distinctly different from those induced by monofunctional mononuclear
platinum(II) compounds, such as [PtCl(dien)]Cl or [PtCl(NH3)3]Cl. A major difference between
DNA modification by monofunctional platinum compounds and bifunctional
dinuclear complexes consists in the ability of the latter to form
interstrand cross-links that effectively prevent separation of the
complementary strands of DNA. It may be that global conformational
changes in the presence of interstrand cross-links will be highly
dependent on sequence. The separation of the DNA strands is essential
for the processes, such as DNA replication or transcription, so that
inhibition of these important processes in tumor cells may represent an
important contribution to the cytostatic effects of the dinuclear complexes.
It has been suggested (21, 23) that HMG domain proteins play a role in
sensitizing cells to cisplatin. It has been shown that HMG domain
proteins recognize and bind to DNA cross-links formed by cisplatin
between bases in neighboring base pairs (21-23). The molecular basis
for this recognition is still not entirely understood, although several
structural details of the 1:1 complex formed between HMG domain and the
duplex containing 1,2 d(GpG) intrastrand cross-link were recently
elucidated (21). The details of how the binding of HMG domain proteins
to cisplatin-modified DNA sensitize tumor cells to cisplatin are also
still not completely resolved, but possibilities such as shielding
cisplatin-DNA adducts from excision repair or that these proteins could
be titrated away from their transcriptional regulatory function have
been suggested (23) as clues for how these proteins are involved in the
antitumor activity.
An important structural motif recognized by HMG domain proteins on DNA
modified by cisplatin is a stable, directional bend of the helix axis
(23). As it is demonstrated in the present work and also in our
previous paper (12) the major interstrand cross-links and even minor
1,2-d(GpG) intrastrand cross-link of trans-bisPt compounds
bend helix axis much less efficiently than the cross-links of cisplatin
(for instance gel retardation assay revealed that 1,2 d(GpG)
intrastrand cross-link of cisplatin produced a rigid, directed bend
32-34° into the major groove of DNA; Ref. 36). Therefore, it was not
surprising that we only observed in the present paper (Fig. 7) very
weak or no recognition of DNA adducts of trans-bisPt
complexes by HMG1 protein, consistent with the assumption that an
important structural motif recognized by HMG domain proteins is bent or
kinked duplex axis. Thus, from the results of the present work, it is
clear that the major DNA adducts of antitumor trans-bisPt
compounds may present a block to DNA or RNA polymerase (14, 19) but are
not a substrate for recognition by HMG domain proteins. From these
considerations we could conclude that the mechanism of antitumor
activity of bifunctional dinuclear platinum complexes does not involve
recognition by HMG domain proteins as a crucial step, in contrast to
the proposals for cisplatin and its direct analogues.
One possible role for binding of HMG domain proteins to DNA modified by
cisplatin is that these proteins shield damaged DNA from intracellular
excision repair (23). The examinations of excision repair of DNA
modified by dinuclear platinum complexes, which form as major DNA
adducts interstrand cross-links, are in progress in our laboratory. In
general, DNA interstrand cross-links pose a special challenge to repair
enzymes because they involve both strands of DNA and therefore cannot
be repaired using the information in the complementary strand for
resynthesis. The fact that interstrand cross-links cannot be removed so
readily by excision repair as intrastrand lesions is also corroborated
by the observation that excision repair of the interstrand cross-link
formed by cisplatin was not detected under condition when intrastrand
adducts of this drug were readily removed by a reconstituted system
containing highly purified nucleotide excision repair factors (63).
Hence, the major DNA adducts of bifunctional dinuclear platinum
compounds would not have to be shielded by damaged DNA recognition
proteins, such as are those containing HMG domains, to prevent their repair.
In conclusion, the results of the present work provide additional
strong support for the hypothesis that platinum drugs that bind to DNA
in a fundamentally different manner to that of cisplatin have altered
pharmacological properties. Importantly, in contrast to cisplatin, the
mediation of antitumor properties of bifunctional dinuclear platinum
complexes by HMG domain proteins is unlikely so that polynuclear
platinum compounds may represent a novel class of platinum anticancer
drugs acting by a different mechanism than cisplatin and its analogues.
A further understanding of how bifunctional dinuclear and other
polynuclear platinum compounds modify DNA and how these modifications
are further processed in cells should provide a rational basis for the
design of new chemotherapeutic strategies and platinum antitumor drugs
rather than searching for cisplatin analogues.
 |
FOOTNOTES |
*
This work was supported by Grants 305/99/0695 and
307/97/P029 from the Grant Agency of the Czech Republic, Grant A5004702 from the Grant Agency of the Academy of Sciences of the Czech Republic,
and National Science Foundation operating grants (to N. F.). This
work is funded in part through Grant ME 152 from the U.S.-Czech
International Cooperation Program of the National Science Foundation
and the Ministry of Education of the Czech Republic.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Recipient of an International Research Scholar's award from
the Howard Hughes Medical Institute. To whom correspondence should be
addressed: Inst. of Biophysics, Academy of Sciences of the Czech
Republic, Kralovopolska 135, CZ-61265 Brno, Czech Republic. Tel.:
420-5-41517148; Fax: 420-5-41211293; E-mail: brabec@ibp.cz.
Published, JBC Papers in Press, March 16, 2000, DOI 10.1074/jbc.M000777200
 |
ABBREVIATIONS |
The abbreviations used are:
cisplatin, cis-diamminedichloroplatinum(II);
trans-bisPt(n), [{trans-PtCl(NH3)2}H2N(CH2)nNH2]Cl2;
HMG, high mobility group;
DMS, dimethyl sulfate;
bp, base pair(s);
DEPC, diethyl pyrocarbonate;
FPLC, fast protein liquid
chromatography.
 |
REFERENCES |
| 1.
|
Chaney, S. G.,
and Sancar, A.
(1996)
J. Natl. Cancer Inst.
88,
1346-1360
|
| 2.
|
Lokich, J.,
and Anderson, N.
(1998)
Ann. Oncol.
9,
13-21
|
| 3.
|
O'Dwyer, P. J.,
Stevenson, J. P.,
and Johnson, S. W.
(1999)
in
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(Lippert, B., ed)
, pp. 31-72, Verlag Helvetica Chimica Acta, Wiley-VCH, Zürich
|
| 4.
|
Johnson, N. P.,
Butour, J.-L.,
Villani, G.,
Wimmer, F. L.,
Defais, M.,
Pierson, V.,
and Brabec, V.
(1989)
Prog. Clin. Biochem. Med.
10,
1-24
|
| 5.
|
Lepre, C. A.,
and Lippard, S. J.
(1990)
Nucleic Acids Mol. Biol.
4,
9-38
|
| 6.
| Leng, M., and Brabec, V. (1994) in DNA Adducts: Identification
and Biological Significance (Hemminki, K., Dipple, A., Shuker,
D. E. G., Kadlubar, F. F., Segerbäck, D., and
Bartsch, H., eds) IARC Scientific Publications No. 125, pp. 339-348,
International Agency for Research on Cancer, Lyon
|
| 7.
|
Blommaert, F. A.,
van Dijk-Knijnenburg, H. C. M.,
Dijt, F. J.,
Denengelse, L.,
Baan, R. A.,
Berends, F.,
and Fichtinger-Schepman, A. M. J.
(1995)
Biochemistry
34,
8474-8480
|
| 8.
|
Woynarowski, J. M.,
Chapman, W. G.,
Napier, C.,
Herzig, M. C. S.,
and Juniewicz, P.
(1998)
Mol. Pharmacol.
54,
770-777
|
| 9.
|
Raymond, E.,
Chaney, S. G.,
Taamma, A.,
and Cvitkovic, E.
(1998)
Ann. Oncol.
9,
1053-1071
|
| 10.
|
Farrell, N.,
Qu, Y.,
Bierbach, U.,
Valsecchi, M.,
and Menta, E.
(1999)
in
30 Years of Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(Lippert, B., ed)
, pp. 479-496, Verlag Helvetica Chimica Acta, Wiley-VCH, Zurich
|
| 11.
|
Farrell, N.,
Appleton, T. G.,
Qu, Y.,
Roberts, J. D.,
Fontes, A. P. S.,
Skov, K. A.,
Wu, P.,
and Zou, Y.
(1995)
Biochemistry
34,
15480-15486
|
| 12.
|
Kasparkova, J.,
Mellish, K. J.,
Qu, Y.,
Brabec, V.,
and Farrell, N.
(1996)
Biochemistry
35,
16705-16713
|
| 13.
|
Mellish, K. J.,
Qu, Y.,
Scarsdale, N.,
and Farrell, N.
(1997)
Nucleic Acids Res.
25,
1265-1271
|
| 14.
|
Zaludova, R.,
Zakovska, A.,
Kasparkova, J.,
Balcarova, Z.,
Kleinwachter, V.,
Vrana, O.,
Farrell, N.,
and Brabec, V.
(1997)
Eur. J. Biochem.
246,
508-517
|
| 15.
|
Kasparkova, J.,
Novakova, O.,
Vrana, O.,
Farrell, N.,
and Brabec, V.
(1999)
Biochemistry
38,
10997-11005
|
| 16.
|
Brabec, V.,
Kasparkova, J.,
Vrana, O.,
Novakova, O.,
Cox, J. W.,
Qu, Y.,
and Farrell, N.
(1999)
Biochemistry
38,
6781-6790
|
| 17.
|
Brabec, V.,
and Leng, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5345-5349
|
| 18.
|
Vrana, O.,
Boudny, V.,
and Brabec, V.
(1996)
Nucleic Acids Res.
24,
3918-3925
|
| 19.
|
Zou, Y.,
Van Houten, B.,
and Farrell, N.
(1994)
Biochemistry
33,
5404-5410
|
| 20.
|
Zlatanova, J.,
Yaneva, J.,
and Leuba, S. H.
(1998)
FASEB
12,
791-799
|
| 21.
|
Ohndorf, U. M.,
Rould, M. A.,
He, Q.,
Pabo, C. O.,
and Lippard, S. J.
(1999)
Nature
399,
708-712
|
| 22.
|
Kasparkova, J.,
and Brabec, V.
(1995)
Biochemistry
34,
12379-12387
|
| 23.
|
Zamble, D. B.,
and Lippard, S. J.
(1999)
in
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(Lippert, B., ed)
, pp. 73-110, VHCA, WILEY-VCH, Zürich
|
| 24.
|
Farrell, N.,
Qu, Y.,
Feng, L.,
and Van Houten, B.
(1990)
Biochemistry
29,
9522-9531
|
| 25.
|
Brabec, V.,
Reedijk, J.,
and Leng, M.
(1992)
Biochemistry
31,
12397-12402
|
| 26.
|
Stros, M.,
and Vorlickova, M.
(1990)
Int. J. Biol. Macromol.
12,
282-288
|
| 27.
|
Stros, M.,
Reich, J.,
and Kolibalova, A.
(1994)
FEBS Lett.
344,
201-206
|
| 28.
|
Comess, K. M.,
Costello, C. E.,
and Lippard, S. J.
(1990)
Biochemistry
29,
2102-2110
|
| 29.
|
Lemaire, M. A.,
Schwartz, A.,
Rahmouni, A. R.,
and Leng, M.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1982-1985
|
| 30.
|
Maxam, A. M.,
and Gilbert, W.
(1980)
Methods Enzymol.
65,
499-560
|
| 31.
|
Brabec, V.,
Sip, M.,
and Leng, M.
(1993)
Biochemistry
32,
11676-11681
|
| 32.
|
Bailly, C.,
Gentle, D.,
Hamy, F.,
Purcell, M.,
and Waring, M. J.
(1994)
Biochem. J.
300,
165-173
|
| 33.
|
Ross, S. A.,
and Burrows, C. J.
(1996)
Nucleic Acids Res.
24,
5062-5063
|
| 34.
|
Bailly, C.,
and Waring, M. J.
(1997)
in
Drug-DNA Interaction Protocols
(Fox, K. R., ed)
, pp. 51-79, Humana Press Inc., Totowa, NJ
|
| 35.
|
Koo, H. S.,
Wu, H. M.,
and Crothers, D. M.
(1986)
Nature
320,
501-506
|
| 36.
|
Bellon, S. F.,
and Lippard, S. J.
(1990)
Biophys. Chem.
35,
179-188
|
| 37.
|
Bianchi, M. E.,
Beltrame, M.,
and G., P.
(1989)
Science
243,
1056-1059
|
| 38.
|
Dalbies, R.,
Payet, D.,
and Leng, M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
8147-8151
|
| 39.
|
Lemaire, M.,
Thauvette, L.,
Deforesta, B.,
Viel, A.,
Beauregard, G.,
and Potier, M.
(1990)
Biochem. J.
267,
431-439
|
| 40.
|
Nielsen, P. E.
(1990)
J. Mol. Recog.
3,
1-24
|
| 41.
|
McCarthy, J. G.,
Williams, L. D.,
and Rich, A.
(1990)
Biochemistry
29,
6071-6081
|
| 42.
|
McCarthy, J. G.,
and Rich, A.
(1991)
Nucleic Acids Res.
19,
3421-3429
|
| 43.
|
Herr, W.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
8009-8013
|
| 44.
|
Johnston, B. H.,
and Rich, A.
(1985)
Cell
42,
713-724
|
| 45.
|
Koo, H. S.,
and Crothers, D. M.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
1763-1767
|
| 46.
|
Rice, J. A.,
Crothers, D. M.,
Pinto, A. L.,
and Lippard, S. J.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
4158-4161
|
| 47.
|
Leng, M.
(1990)
Biophys. Chem.
35,
155-163
|
| 48.
|
Huang, H. F.,
Zhu, L. M.,
Reid, B. R.,
Drobny, G. P.,
and Hopkins, P. B.
(1995)
Science
270,
1842-1845
|
| 49.
|
Bellon, S. F.,
Coleman, J. H.,
and Lippard, S. J.
(1991)
Biochemistry
30,
8026-8035
|
| 50.
|
Wang, J. C.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
200-203
|
| 51.
|
Rhodes, D.,
and Klug, A.
(1980)
Nature
286,
573-578
|
| 52.
|
Malinge, J. M.,
Perez, C.,
and Leng, M.
(1994)
Nucleic Acids Res.
22,
3834-3839
|
| 53.
|
Zinkel, S.,
and Crothers, D. M.
(1987)
Nature
328,
178-181
|
| 54.
|
Koo, H. S.,
Drak, J.,
Rice, J. A.,
and Crother |